Objective: To profile telomere-related genes (TRGs) to develop a robust prognostic tool for stomach adenocarcinoma (STAD) and explore their associations with immune regulation and treatment response.
Methods: A total of 2083 TRGs were analyzed in The Cancer Genome Atlas (TCGA)-STAD cohort (412 tumor and 36 normal samples) and external validation was performed using the GSE84437 dataset. A prognostic model was constructed through differential expression analysis, univariate Cox regression, and least absolute shrinkage and selection operator Cox regression. Model performance was evaluated using Kaplan–Meier survival analysis, multivariable Cox regression, time-dependent receiver operating characteristic curves, and nomogram construction. Associations with immune cell infiltration, tumor mutation burden (TMB), tumor immune dysfunction and exclusion (TIDE), and drug sensitivity were assessed. The expression patterns of the signature genes were experimentally validated using quantitative reverse transcription polymerase chain reaction and Western blot analysis in human gastric cancer cell lines and an N-methyl-N′-nitro-N-nitrosoguanidine induced rat gastric adenocarcinoma model.
Results: An eight-TRG signature (ANXA5, ELOVL2, INCENP, NFE2L3, NOS3, RASGEF1C, REPIN1, and SOAT1) effectively predicted overall survival in the TCGA and GSE84437 cohorts, independent of clinicopathological factors (1-, 3-, and 5-year area under curves: 0.682, 0.695, and 0.697, respectively). The expression of seven genes were upregulated in tumor tissues, whereas that of RASGEF1C was downregulated. The derived risk score correlated with immune infiltration, TMB, and TIDE scores, and predicted drug sensitivities differed between the risk groups. Reverse transcription quantitative polymerase chain reaction analysis further validated the expression patterns of these genes in cell lines.In vitro and in vivo assays corroborated the bioinformatics findings, confirming the dysregulation of key signature genes in tumor cells and tissues at the mRNA and protein levels.
Conclusions: The eight-TRG signature provides reliable prognostic stratification for STAD and links telomere biology to the immune context and therapy response.
Funding
This work was supported by the National Natural Science Foundation of China (82374292), Noncommunicable Chronic Diseases-National Science and Technology Major Project (2025ZD0545100), Innovation Team, and Talents Cultivation Program of the National Administration of Traditional Chinese Medicine (ZYYCXTD-C-202401), Plans for Major Provincial Science and Technology Projects of Anhui Province (202303a0702003), and Fundamental Research Funds for the Central Universities of Beijing University of Chinese Medicine (2025-JYB-JBGS-025 and 90011451310100).
CRediT authorship contribution statement
Xingjian Song: Writing ‒ original draft, formal analysis, and investigation. Qingsong Qu: Writing ‒ original draft. Yuan Gao: Validation. Chongyan Zhao: Validation. Lei Sun: Conceptualization. Wanhong Zhu: Methodology. Jingqi Zeng: Data curation, and visualization. Xia Ding: Conceptualization, project administration, supervision, funding acquisition, resources, and writing ‒ review & editing.
Declaration of competing interest
The authors declare that there are no conflicts of interest. Prof. Xia Ding is an editorial board member of Journal of Traditional Chinese Medical Sciences. She was excluded from the review process of this paper.
| [1] |
Guan WL, He Y, Xu RH . Gastric cancer treatment: recent progress and future perspectives. J Hematol Oncol. 2023; 16(1): 57.
|
| [2] |
Zavros Y, Merchant JL . The immune microenvironment in gastric adenocarcinoma. Nat Rev Gastroenterol Hepatol. 2022; 19(7): 451-467.
|
| [3] |
Smyth EC, Nilsson M, Grabsch HI, Van Grieken NC, Lordick F . Gastric cancer. Lancet. 2020; 396(10251): 635-648.
|
| [4] |
Jiang Y, Wang H, Wu J, et al. Noninvasive imaging evaluation of tumor immune microenvironment to predict outcomes in gastric cancer. Ann Oncol. 2020; 31(6): 760-768.
|
| [5] |
Zubarayev M, Min EK, Son T . Clinical and molecular prognostic markers of survival after surgery for gastric cancer: tumor—node—metastasis staging system and beyond. Transl Gastroenterol Hepatol. 2019; 4: 59.
|
| [6] |
Chen Y, Jia K, Sun Y, et al. Predicting response to immunotherapy in gastric cancer via multi—dimensional analyses of the tumour immune microenvironment. Nat Commun. 2022; 13(1): 4851.
|
| [7] |
Chakravarti D, LaBella KA, DePinho RA . Telomeres: history, health, and hallmarks of aging. Cell. 2021; 184(2): 306-322.
|
| [8] |
Rossiello F, Jurk D, Passos JF, d'Adda di Fagagna F . Telomere dysfunction in ageing and age—related diseases. Nat Cell Biol. 2022; 24(2): 135-147.
|
| [9] |
Hoang SM, O'Sullivan RJ . Alternative lengthening of telomeres: building bridges to connect chromosome ends. Trends Cancer. 2020; 6(3): 247-260.
|
| [10] |
Shou S, Maolan A, Zhang D, et al. Telomeres, telomerase, and cancer: mechanisms, biomarkers, and therapeutics. Exp Hematol Oncol. 2025; 14(1): 8.
|
| [11] |
Borges G, Criqui M, Harrington L . Tieing together loose ends: telomere instability in cancer and aging. Mol Oncol. 2022; 16(18): 3380-3396.
|
| [12] |
Nassour J, Schmidt TT, Karlseder J . Telomeres and cancer: resolving the paradox. Annu Rev Cell Biol. 2021; 5(1): 59-77.
|
| [13] |
Ebata H, Loo TM, Takahashi A . Telomere maintenance and the cGAS—STING pathway in cancer. Cells. 2022; 11(12): 1958.
|
| [14] |
Turk H, Hamilton S, Siu L, June C, Ott P . Clinical trials in the evolving landscape of precision medicine. Cancer Cell. 2020; 38(1): 3-8.
|
| [15] |
Chen S, Hu S, Zhou B, et al. Telomere—related prognostic biomarkers for survival assessments in pancreatic cancer. Sci Rep. 2023; 13(1): 10586.
|
| [16] |
Godonu SS, Brown D, Steffi A . Catalytic ROS Therapy in Glioblastoma: A Review of the Disruptive Strategy to Target Telomerase, Induce Apoptosis, and Redefine Cancer Treatment. 2025.
|
| [17] |
Kang WS, Jung WK, Park SB, Kim HR, Kim J . Gemigliptin suppresses salivary dysfunction in streptozotocin—induced diabetic rats. Biomed Pharmacother. 2021; 137: 111297.
|
| [18] |
Ligibel JA, Reply to, Chlebowski RT. J Clin Oncol. 2020; 38(26): 3072-3073.
|
| [19] |
Sant GR, Knopf KB, Albala DM . Live—single—cell phenotypic cancer biomarkers—future role in precision oncology? npj Precis Oncol. 2017; 1(1): 21.
|
| [20] |
Sung JY, Hwang K . Telomere maintenance meets cancer metabolism: mechanistic insights and clinical opportunities. Crit Rev Oncol Hematol. 2025; 217: 105017.
|
| [21] |
Zhu XX, Li JH, Ni X, et al. Pancreatic ductal adenocarcinoma cells regulated the gemcitabine—resistance function of CAFs by LINC00460. Cancer Sci. 2022; 113(11): 3735-3750.
|
| [22] |
Gao J, Pickett HA . Targeting telomeres: advances in telomere maintenance mechanism—specific cancer therapies. Nat Rev Cancer. 2022; 22(9): 515-532.
|
| [23] |
Karamat U, Yang R, Ren Y, Lu Y, Li N, Zhao J . Comprehensive In silico characterization and expression profiling of DA1/DAR family genes in Brassica rapa . Genes. 2022; 13(9): 1577.
|
| [24] |
Li Y, Li T, Chen J, et al. Manpixiao decoction halted the malignant transformation of precancerous lesions of gastric cancer: from network prediction to in vivo verification . Front Pharmacol. 2022; 13: 927731.
|
| [25] |
Lu L, Chen B, Zhang X, et al. The effect of phytochemicals in N—methyl—N—nitro—N—nitroguanidine promoting the occurrence and development of gastric cancer. Front Pharmacol. 2023; 14: 1203265.
|
| [26] |
Wei Y, Zhang J, Fan X, et al. Immune profiling in gastric cancer reveals the dynamic landscape of immune signature underlying tumor progression. Front Immunol. 2022; 13: 935552.
|
| [27] |
Ma M, Sun J, Liu Z, et al. The immune microenvironment in gastric cancer: prognostic prediction. Front Oncol. 2022; 12: 836389.
|
| [28] |
Chu G, Ji X, Wang Y, Niu H . Integrated multiomics analysis and machine learning refine molecular subtypes and prognosis for muscle—invasive urothelial cancer. Mol Ther Nucleic Acids. 2023; 33: 110-126.
|
| [29] |
Li Q, Liu H . Investigating the prognostic role of telomerase—related cellular senescence gene signatures in breast cancer using machine learning. Biomedicines. 2025; 13(4): 826.
|
| [30] |
Zhang Y, Fan J, Zhao J, Zhu H, Xia Y, Xu H . A telomere—associated molecular landscape reveals immunological, microbial, and therapeutic heterogeneity in colorectal cancer. Front Mol Biosci. 2025; 12: 1615533.
|
| [31] |
Chen X, Han M, Li Y, Li X, Zhang J, Zhu Y . Identification of functional gene modules by integrating multi—omics data and known molecular interactions. Front Genet. 2023; 14: 1082032.
|
| [32] |
Huang Y, Zhou X, Li X, Huang D, Fang Z, Ding R . A pan—cancer analysis identifies SOAT1 as an immunological and prognostic biomarker. Oncol Res. 2023; 31(2): 193-205.
|
| [33] |
Wang X, Yu H, Gao R, Liu M, Xie W . A comprehensive review of the family of very—long—chain fatty acid elongases: structure, function, and implications in physiology and pathology. Eur J Med Res. 2023; 28(1): 532.
|
| [34] |
Wang Z, Wang M, Zhang M, et al. High—affinity SOAT1 ligands remodeled cholesterol metabolism program to inhibit tumor growth. BMC Med. 2022; 20(1): 292.
|
| [35] |
Krüger J, Berger C, Weidle K, et al. Metabolic effects of genetic variation in the human REPIN1 gene. Int J Obes. 2019; 43(4): 821-831.
|
| [36] |
Liu M, Wei H, Yang J, et al. Multi—omics analysis of molecular characteristics and carcinogenic effect of NFE2L3 in pan—cancer. Front Genet. 2022; 13: 916973.
|
| [37] |
Liu J, Liu X, Zeng Y, et al. RASGEF1C as a novel prognostic biomarker for LUAD. Discov Oncol. 2024; 15(1): 825.
|
| [38] |
Sun M, Veschi V, Bagchi S, et al. Targeting the chromosomal passenger complex subunit INCENP induces polyploidization, apoptosis, and senescence in neuroblastoma. Cancer Res. 2019; 79(19): 4937-4950.
|
| [39] |
Vader G, Maia AF, Lens SM . The chromosomal passenger complex and the spindle assembly checkpoint: kinetochore—microtubule error correction and beyond. Cell Div. 2008; 3: 10.
|
| [40] |
Wu H, Zheng K, Han F . RASGEF1C affects aerobic glycolysis and facilitates lung cancer progression through the PLK1 signaling pathway. Expert Rev Anticancer Ther. 2025; 25(8): 961-971.
|
| [41] |
Chen Y, Sun Z, Chen W, et al. The immune subtypes and landscape of gastric cancer and to predict based on the whole—slide images using deep learning. Front Immunol. 2021; 12: 685992.
|
| [42] |
Wang J, Li D, Cang H, Guo B . Crosstalk between cancer and immune cells: role of tumor—associated macrophages in the tumor microenvironment. Cancer Med. 2019; 8(10): 4709-4721.
|
| [43] |
Wu B, Zhang B, Li B, Wu H, Jiang M . Cold and hot tumors: from molecular mechanisms to targeted therapy. Signal Transduct Targeted Ther. 2024; 9(1): 274.
|
| [44] |
Yang W, Liu S, Mao M, et al. T—cell infiltration and its regulatory mechanisms in cancers: insights at single—cell resolution. J Exp Clin Cancer Res. 2024; 43(1): 38.
|
| [45] |
Jiang P, Gu S, Pan D, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018; 24(10): 1550-1558.
|
| [46] |
Strickler JH, Hanks BA, Khasraw M . Tumor mutational burden as a predictor of immunotherapy response: is more always better? Clin Cancer Res. 2021; 27(5): 1236-1241.
|
| [47] |
Veas Rodriguez J, Piñol M, Sorolla MA, et al. Comprehensive immunophenotyping of gastric adenocarcinoma identifies an inflamed class of tumors amenable to immunotherapies. J Immunother Cancer. 2025; 13(3): e010024.
|
| [48] |
Jang JY, Jeon Y, Jeong SY, et al. The optimal tumor mutational burden cutoff value as a novel marker for predicting the efficacy of programmed cell death—1 checkpoint inhibitors in advanced gastric cancer. J Gastric Cancer. 2023; 23(3): 476.
|
| [49] |
Wang X, Li Y, Fang Z, Li Y . Elevated expression of NFE2L3 promotes the development of gastric cancer through epithelial—mesenchymal transformation. Bioengineered. 2021; 12(2): 12204-12214.
|
| [50] |
Hong Z, Wen P, Wang K, et al. The macrophage—associated prognostic gene ANXA5 promotes immunotherapy resistance in gastric cancer through angiogenesis. BMC Cancer. 2024; 24(1): 141.
|
| [51] |
Zhu T, Wang Z, Zou T, et al. SOAT1 promotes gastric cancer lymph node metastasis through lipid synthesis. Front Pharmacol. 2021; 12: 769647.
|
| [52] |
Zou D, Li Z, Lv F, et al. Pan—cancer analysis of NOS3 identifies its expression and clinical relevance in gastric cancer. Front Oncol. 2021; 11: 592761.
|
| [53] |
Kumar V, Ramnarayanan K, Sundar R, et al. Single—cell atlas of lineage states, tumor microenvironment, and subtype—specific expression programs in gastric cancer. Cancer Discov. 2022; 12(3): 670-691.
|
| [54] |
Ma H, Srivastava S, Ho SWT, et al. Spatially resolved tumor ecosystems and cell states in gastric adenocarcinoma progression and evolution. Cancer Discov. 2025; 15(4): 767-792.
|
| [55] |
Su Z, Shu K, Li G . Increased ANXA5 expression in stomach adenocarcinoma infers a poor prognosis and high level of immune infiltration. Cancer Biomarkers. 2022; 35(2): 155-165.
|
| [56] |
Su R, Chen J, Dai C, et al. The molecular subtype based on cell cycle—related gene signature predicts the prognosis and chemotherapy and immunotherapy response in gastric cancer. Sci Rep. 2025; 15(1): 20858.
|
| [57] |
Mao Y, Gide TN, Adegoke NA, et al. Cross—platform comparison of immune signatures in immunotherapy—treated patients with advanced melanoma using a rank—based scoring approach. J Transl Med. 2023; 21(1): 257.
|
PDF
